Fenestrated Endovascular Repair for Pararenal or Juxtarenal Abdominal Aortic Aneurysms: a Systematic Review.


Journal

Annals of vascular surgery
ISSN: 1615-5947
Titre abrégé: Ann Vasc Surg
Pays: Netherlands
ID NLM: 8703941

Informations de publication

Date de publication:
Feb 2020
Historique:
received: 04 08 2019
revised: 12 09 2019
accepted: 12 09 2019
pubmed: 21 10 2019
medline: 7 7 2020
entrez: 21 10 2019
Statut: ppublish

Résumé

This review aims to collect all available data on early and late outcomes in patients undergoing fenestrated endovascular aortic aneurysm repair (F-EVAR) for pararenal or juxtarenal abdominal aortic aneurysms (AAAs). The Pubmed, Embase, Scopus and Cochrane Library databases were systematically searched to identify eligible studies. Studies reporting at least early mortality after F-EVAR in patients with pararenal or juxtarenal AAA were included. Thirty-day outcomes were defined as early, and outcomes reported after 30 days postoperatively were defined as late. Basic characteristics of all studies and demographics of patients were reported. Overall, 30 studies (17 retrospective and 13 prospective) including 23,385 patients in total were included. Out of 23,385 patients, a total of 2,271 patients were treated with F-EVAR for pararenal/juxtarenal AAA. Overall, 4,216 target vessels were to be treated (data from 24 studies). Pooled early mortality reached 2.55% (ranging from 0% to 6.74%), with a pooled technical success of 96.8% (ranging from 82.8% to 100%). Regarding late outcomes, pooled all-cause mortality reached 17% (ranging from 0% to 50%), 1-year primary patency was 94.6% (ranging from 91.8% to 97.1%) and reintervention rate was 10.4% (ranging from 0% to 57.4%). Mean/median follow-up ranged from 3 to 60 months. Early outcomes indicate that F-EVAR is a safe and efficient treatment for patients with pararenal/juxtarenal AAAs. Although long-term outcomes are acceptable, late-intervention rate remains high.

Sections du résumé

BACKGROUND BACKGROUND
This review aims to collect all available data on early and late outcomes in patients undergoing fenestrated endovascular aortic aneurysm repair (F-EVAR) for pararenal or juxtarenal abdominal aortic aneurysms (AAAs).
METHODS METHODS
The Pubmed, Embase, Scopus and Cochrane Library databases were systematically searched to identify eligible studies. Studies reporting at least early mortality after F-EVAR in patients with pararenal or juxtarenal AAA were included. Thirty-day outcomes were defined as early, and outcomes reported after 30 days postoperatively were defined as late. Basic characteristics of all studies and demographics of patients were reported.
RESULTS RESULTS
Overall, 30 studies (17 retrospective and 13 prospective) including 23,385 patients in total were included. Out of 23,385 patients, a total of 2,271 patients were treated with F-EVAR for pararenal/juxtarenal AAA. Overall, 4,216 target vessels were to be treated (data from 24 studies). Pooled early mortality reached 2.55% (ranging from 0% to 6.74%), with a pooled technical success of 96.8% (ranging from 82.8% to 100%). Regarding late outcomes, pooled all-cause mortality reached 17% (ranging from 0% to 50%), 1-year primary patency was 94.6% (ranging from 91.8% to 97.1%) and reintervention rate was 10.4% (ranging from 0% to 57.4%). Mean/median follow-up ranged from 3 to 60 months.
CONCLUSIONS CONCLUSIONS
Early outcomes indicate that F-EVAR is a safe and efficient treatment for patients with pararenal/juxtarenal AAAs. Although long-term outcomes are acceptable, late-intervention rate remains high.

Identifiants

pubmed: 31629840
pii: S0890-5096(19)30854-4
doi: 10.1016/j.avsg.2019.09.016
pii:
doi:

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

399-408

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Naser Mohamed (N)

Department of Vascular Surgery, KAT General Hospital, Athens, Greece.

George Galyfos (G)

First Propaedeutic Department of Surgery, University of Athens Medical School, Hippocration Hospital, Athens, Greece. Electronic address: georgegalyfos@hotmail.com.

Christiana Anastasiadou (C)

Department of Vascular Surgery, KAT General Hospital, Athens, Greece.

Ioannis Sachmpatzidis (I)

Department of Vascular Surgery, KAT General Hospital, Athens, Greece.

Konstantinos Kikiras (K)

Department of Vascular Surgery, KAT General Hospital, Athens, Greece.

Anastasios Papapetrou (A)

Department of Vascular Surgery, KAT General Hospital, Athens, Greece.

Sotirios Giannakakis (S)

Department of Vascular Surgery, KAT General Hospital, Athens, Greece.

Georgios Kastrisios (G)

Department of Vascular Surgery, KAT General Hospital, Athens, Greece.

Gerasimos Papacharalampous (G)

Department of Vascular Surgery, KAT General Hospital, Athens, Greece.

Georgios Geroulakos (G)

Department of Vascular Surgery, University of Athens Medical School, Attikon Hospital, Athens, Greece.

Chrisostomos Maltezos (C)

Department of Vascular Surgery, KAT General Hospital, Athens, Greece.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH